We are delighted to announce that we have been awarded two prestigious and highly competitive grants to investigate new therapeutic approaches against pancreatic ductal adenocarcinomas (PDAC), the most common type of pancreatic cancer.
Pancreatic cancer is a silent and deadly disease, for which no satisfactory treatment is currently available. Due to its asymptomatic nature, pancreatic cancer is mostly diagnosed at an advanced stage with dismal outcomes: median survival drops below six months without treatment, and mostly under one year with standard of care. Over the last decades, patient outcome and survival has merely improved, while the incidence and mortality of pancreatic cancer continue to rise alarmingly. As a result, this disease is widely recognized as a health priority and societal challenge, for which new therapies are urgently needed.
In this context, we are committed to explore new therapeutic avenues to bring hope to the patients. We are delighted to announce that two projects focusing on PDAC have recently been funded: project PACMAN under the ERC Proof of Concept scheme, and PANCLAU under the ARC PANCREAS program. These two grants of €150,000 and €450,000 respectively, will enable us to extend our research scope to pancreatic cancer, by pursuing complementary experiments and exploiting a variety of patient derived models. While each project is fully independent from the other, the combination of both efforts will allow us to build a strong pre-clinical study of a new therapeutic candidate and offer us extensive insights into the disease biology and mechanism of action, with the aim to bring a new drug to the market.
đź”— External links: